{
    "id": 25529,
    "fullName": "GUCY2C positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "GUCY2C positive indicates the presence of the GUCY2C gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2984,
        "geneSymbol": "GUCY2C",
        "terms": [
            "GUCY2C",
            "DIAR6",
            "GC-C",
            "GUC2C",
            "MECIL",
            "MUCIL",
            "STAR"
        ]
    },
    "variant": "positive",
    "createDate": "10/17/2016",
    "updateDate": "04/25/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8887,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, TAK-264 (MLN0624) demonstrated safety in patients with GUCY2C (GCC)-expressing gastrointestinal cancers, and demonstrated preliminary efficacy in patients with esophageal, gastric, and pancreatic carcinoma (PMID: 27178743).",
            "molecularProfile": {
                "id": 26528,
                "profileName": "GUCY2C positive"
            },
            "therapy": {
                "id": 4845,
                "therapyName": "TAK-264",
                "synonyms": null
            },
            "indication": {
                "id": 3119,
                "name": "gastrointestinal system cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6783,
                    "pubMedId": 27178743,
                    "title": "Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27178743"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26528,
            "profileName": "GUCY2C positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}